RMS, or rhabdomyosarcoma, is a cancer that develops in soft tissue, specifically in cells that normally grow into skeletal muscle. It is the most common soft tissue cancer in children, typically diagnosed in kids under age 10, though it can also appear in teenagers and adults. RMS tumors can form nearly anywhere in the body since muscle tissue is widespread, but they most often develop in the head and neck region (about 25% of cases), the genitourinary tract (about 31%), and the extremities (about 13%).
Types of Rhabdomyosarcoma
RMS comes in several distinct subtypes, and the type matters because it affects both how the cancer behaves and how well it responds to treatment.
Embryonal RMS is the most common form. It primarily affects young children between birth and age 5, and tends to develop in the head, neck, or genitourinary tract. This subtype generally carries a more favorable prognosis compared to other types.
Alveolar RMS typically appears in older children and teenagers, between ages 10 and 20. It is more likely to develop in the arms or legs and carries a poorer prognosis. Alveolar RMS is defined in part by a specific genetic change: a fusion between genes on two different chromosomes. This fusion acts as a molecular fingerprint that helps confirm the diagnosis and also signals more aggressive disease. Patients whose tumors carry this genetic marker (called fusion-positive) tend to have worse outcomes than those without it.
Pleomorphic RMS is the adult form. It also favors the extremities and tends to grow rapidly as a painful mass. Prognosis is generally poor.
A fourth subtype, spindle cell/sclerosing RMS, can occur across all age groups and appears in locations like the head, neck, or near the testicles.
Symptoms by Location
Because RMS can form in so many parts of the body, symptoms vary widely depending on where the tumor grows. This is part of what makes it tricky to recognize early.
Tumors in the head and neck area, including around the eye socket, sinuses, or nasal passages, can cause persistent nasal congestion, thick nasal drainage, or a bulging eye. When the tumor grows near the genitourinary tract, it may cause pelvic pain, blood in the urine, difficulty urinating, frequent urination, or abnormal vaginal bleeding. Tumors in the arms or legs often appear as a painless lump, though the adult form (pleomorphic) more commonly presents as a rapidly growing, painful mass.
Many of these symptoms overlap with common childhood illnesses, which is one reason RMS can go undiagnosed for weeks or months before the tumor becomes large enough or persistent enough to prompt further testing.
How RMS Is Diagnosed
MRI is the primary imaging tool for evaluating an RMS tumor because it provides the most detailed picture of the tumor and the surrounding tissues. To check whether the cancer has spread to nearby lymph nodes, doctors combine MRI with a PET/CT scan, which highlights areas of abnormal metabolic activity throughout the body. A separate CT scan of the chest is done to look for any spread to the lungs.
Imaging alone cannot confirm a diagnosis. A biopsy, either a core-needle biopsy guided by imaging or a surgical incision biopsy, is required. Importantly, a full imaging workup is completed before the biopsy because the biopsy tract itself needs to be planned carefully. If surgery is eventually needed, that tract must be included in the area that gets removed.
Risk Groups and Prognosis
Once diagnosed, RMS is classified into risk groups (low, intermediate, or high) that guide treatment decisions. The Children’s Oncology Group assigns risk based on several factors: where the tumor is located, how much it has spread, whether it can be surgically removed, the patient’s age, and the tumor’s genetic fusion status.
Tumor location plays a significant role. The orbit (eye socket), most head and neck sites, and parts of the genitourinary tract are considered favorable locations because tumors there tend to respond better to treatment. Tumors near the brain membranes (parameningeal sites), in the bladder or prostate, or in the arms and legs are considered unfavorable.
Fusion status has become one of the most important prognostic markers. Fusion-positive tumors, those carrying the gene rearrangement typical of alveolar RMS, now define higher-risk categories regardless of other factors. This genetic marker has actually replaced the older method of classifying risk based purely on how the tumor looks under a microscope, because it more accurately predicts outcomes. Among fusion-positive cases, those with metastatic disease at any age are placed in the highest risk category.
Children under 10 with fusion-negative tumors that have spread still fall into the intermediate-risk group, while older patients with the same scenario are classified as high-risk. These distinctions directly affect how aggressively the cancer is treated.
Treatment Approach
RMS treatment typically involves a combination of chemotherapy, surgery, and radiation. Nearly all patients receive chemotherapy as a core part of treatment, regardless of risk group, because RMS is responsive to these drugs. Surgery aims to remove as much of the tumor as possible, and radiation therapy targets any remaining cancer cells at the original site.
The specific combination and intensity of treatment depends on the risk group. Low-risk patients receive less aggressive regimens, while high-risk patients undergo more intensive chemotherapy and broader radiation fields. Treatment courses generally span many months and require close monitoring throughout.
Long-Term Effects for Survivors
Because RMS primarily affects children, and because treatment involves powerful therapies applied to growing bodies, survivors face a range of potential long-term health effects that require ongoing monitoring.
Radiation therapy can slow or stop bone and muscle growth in the treated area. Survivors may develop bone density problems, joint pain, or uneven growth depending on which part of the body was irradiated. Bone mineral density scans, X-rays, and blood tests for calcium and vitamin D levels are used to track these changes over time.
Reproductive health is another major concern. Surgery involving the testicles, prostate, ovaries, or pelvic lymph nodes, along with certain chemotherapy drugs and radiation to the pelvis or lower abdomen, can affect fertility. These effects may not become apparent until years after treatment ends.
Digestive tract complications can develop in survivors who were treated for tumors in the bladder, prostate, or near the testicles, particularly when radiation was directed at those areas. Survivors of RMS are recommended to have a comprehensive physical exam at least once a year with a healthcare professional who understands the specific late effects associated with their treatment history. The monitoring plan is individualized based on the cancer type, treatments received, genetic factors, and the survivor’s overall health.